Your browser is no longer supported. Please, upgrade your browser.
LMNL Liminal BioSciences Inc. daily Stock Chart
Liminal BioSciences Inc.
Index- P/E- EPS (ttm)- Insider Own71.39% Shs Outstand23.39M Perf Week13.49%
Market Cap566.78M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.90M Perf Month43.82%
Income- PEG- EPS next Q- Inst Own14.23% Short Float0.22% Perf Quarter139.77%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.12 Perf Half Y84.18%
Book/sh3.36 P/B5.51 EPS next Y- ROA- Target Price- Perf Year-48.58%
Cash/sh1.20 P/C15.49 EPS next 5Y- ROE- 52W Range5.25 - 31.45 Perf YTD120.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.14% Beta1.81
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low252.57% ATR3.41
Employees300 Current Ratio2.70 Sales Q/Q-52.20% Oper. Margin- RSI (14)57.95 Volatility19.00% 16.25%
OptionableNo Debt/Eq0.58 EPS Q/Q96.50% Profit Margin- Rel Volume0.23 Prev Close18.09
ShortableYes LT Debt/Eq0.49 Earnings- Payout- Avg Volume129.53K Price18.51
Recom- SMA2032.41% SMA5050.19% SMA20099.40% Volume29,411 Change2.32%
Aug-06-20 05:01PM  
Jul-22-20 07:55AM  
Jul-17-20 08:00AM  
Jul-02-20 11:16AM  
Jun-30-20 05:31PM  
Jun-11-20 05:00PM  
Jun-09-20 03:53PM  
May-28-20 05:30PM  
May-22-20 07:14AM  
May-13-20 05:00PM  
Mar-23-20 06:30AM  
Mar-22-20 03:23PM  
Mar-20-20 05:01PM  
Feb-12-20 07:30AM  
Feb-06-20 07:30AM  
Jan-13-20 07:00AM  
Dec-23-19 03:43PM  
Nov-28-19 04:40PM  
Nov-27-19 07:30AM  
Nov-25-19 12:03PM  
Nov-18-19 07:30AM  
Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alstrom syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. Liminal BioSciences has partnership with CoVIg plasma alliance for the development of COVID-19 therapy. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.